trihale 200 rotacap dry powder inhaler
the acme laboratories ltd. - fluticasone furoate + umeclidinium + vilanterol - dry powder inhaler - 200 mcg + 62.5 mcg + 25 mcg
trilexa 100/62.5/25 bexicap dry powder inhaler
beximco pharmaceuticals ltd. - fluticasone furoate + umeclidinium + vilanterol - dry powder inhaler - 100 mcg + 62.5 mcg + 25 mcg
viltica-u renacap dry powder inhaler
renata ltd., bhaluka - fluticasone furoate + umeclidinium + vilanterol - dry powder inhaler - 100 mcg + 62.5 mcg + 25 mcg
tritide unicap dry powder inhaler
unimed unihealth pharmaceuticals ltd. - fluticasone furoate + umeclidinium + vilanterol - dry powder inhaler - 100 mcg + 62.5 mcg + 25 mcg
trilexa 200/62.5/25 bexicap dry powder inhaler
beximco pharmaceuticals ltd. - fluticasone furoate + umeclidinium + vilanterol - dry powder inhaler - 200 mcg + 62.5 mcg + 25 mcg
triflo arocap dry powder inhal dry powder inhaler
aristopharma limited - fluticasone furoate + umeclidinium + vilanterol - dry powder inhaler - 100 mcg + 62.5 mcg + 25 mcg
trelogy easycap 100/62.5/25mcg dry powder inhaler
healthcare pharmaceuticals ltd. - fluticasone furoate + umeclidinium + vilanterol - dry powder inhaler - 100 mcg + 62.5 mcg + 25 mcg
arnuity ellipta powder
glaxosmithkline inc - fluticasone furoate - powder - 100mcg - fluticasone furoate 100mcg - corticosteroids
arnuity ellipta powder
glaxosmithkline inc - fluticasone furoate - powder - 200mcg - fluticasone furoate 200mcg - corticosteroids
utibron neohaler- indacaterol and glycopyrrolate capsule
novartis pharmaceuticals corporation - indacaterol maleate (unii: 2jec1itx7r) (indacaterol - unii:8or09251mq), glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - indacaterol 27.5 ug - utibrontm neohaler® is a combination of indacaterol and glycopyrrolate indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. important limitations of use: utibron neohaler is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see warnings and precautions (5.1, 5.2)] . all labas are contraindicated in patients with asthma without use of a long-term asthma control medication [see warnings and precautions (5.1)] . utibron neohaler is not indicated for the treatment of asthma. utibron neohaler is contraindicated in patients who have demonstrated hypersensitivity to indacaterol, glycopyrrolate, or to any of the ingredients [see warnings and precautions (5.5)] . teratogenic effects: pregnancy category c there are no adequate and well-controlled studies with utibron neohaler or its individual components, indacaterol and glycopyrrolate, in pregnant women